MIROMATRIX MEDICAL INC (MIRO) Fundamental Analysis & Valuation
NASDAQ:MIRO • US60471P1084
Current stock price
3.39 USD
+0.02 (+0.59%)
At close:
3.39 USD
0 (0%)
After Hours:
This MIRO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MIRO Profitability Analysis
1.1 Basic Checks
- In the past year MIRO has reported negative net income.
- MIRO had a negative operating cash flow in the past year.
1.2 Ratios
- The Return On Assets of MIRO (-117.04%) is worse than 95.08% of its industry peers.
- Looking at the Return On Equity, with a value of -176.38%, MIRO is doing worse than 88.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -117.04% | ||
| ROE | -176.38% | ||
| ROIC | N/A |
ROA(3y)-102.22%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 47.92%, MIRO is in line with its industry, outperforming 54.10% of the companies in the same industry.
- The Profit Margin and Operating Margin are not available for MIRO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. MIRO Health Analysis
2.1 Basic Checks
- MIRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, MIRO has more shares outstanding
- Compared to 1 year ago, MIRO has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -3.73, we must say that MIRO is in the distress zone and has some risk of bankruptcy.
- MIRO has a Altman-Z score of -3.73. This is amonst the worse of the industry: MIRO underperforms 88.52% of its industry peers.
- A Debt/Equity ratio of 0.03 indicates that MIRO is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.03, MIRO is in line with its industry, outperforming 59.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.73 |
ROIC/WACCN/A
WACC12.72%
2.3 Liquidity
- MIRO has a Current Ratio of 3.46. This indicates that MIRO is financially healthy and has no problem in meeting its short term obligations.
- With a Current ratio value of 3.46, MIRO perfoms like the industry average, outperforming 57.38% of the companies in the same industry.
- A Quick Ratio of 3.46 indicates that MIRO has no problem at all paying its short term obligations.
- MIRO's Quick ratio of 3.46 is fine compared to the rest of the industry. MIRO outperforms 62.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.46 | ||
| Quick Ratio | 3.46 |
3. MIRO Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an nice 17.99% over the past year.
- The Revenue has grown by 3100.00% in the past year. This is a very strong growth!
- MIRO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 56.05% yearly.
EPS 1Y (TTM)17.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.14%
Revenue 1Y (TTM)3100%
Revenue growth 3Y56.05%
Revenue growth 5YN/A
Sales Q2Q%0%
3.2 Future
- The Earnings Per Share is expected to grow by 19.77% on average over the next years. This is quite good.
- MIRO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 490.87% yearly.
EPS Next Y32.47%
EPS Next 2Y18.41%
EPS Next 3Y7.54%
EPS Next 5Y19.77%
Revenue Next Year-6.67%
Revenue Next 2Y-5.13%
Revenue Next 3Y-3.45%
Revenue Next 5Y490.87%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. MIRO Valuation Analysis
4.1 Price/Earnings Ratio
- MIRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year MIRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.41%
EPS Next 3Y7.54%
5. MIRO Dividend Analysis
5.1 Amount
- No dividends for MIRO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MIRO Fundamentals: All Metrics, Ratios and Statistics
3.39
+0.02 (+0.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-14 2023-11-14/amc
Earnings (Next)N/A N/A
Inst Owners22.32%
Inst Owner Change-7.87%
Ins Owners108.14%
Ins Owner Change0%
Market Cap92.95M
Revenue(TTM)960.00K
Net Income(TTM)-27.41M
Analysts80
Price Target3.19 (-5.9%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.41%
Min EPS beat(2)-12.04%
Max EPS beat(2)18.86%
EPS beat(4)2
Avg EPS beat(4)3.41%
Min EPS beat(4)-12.04%
Max EPS beat(4)18.86%
EPS beat(8)3
Avg EPS beat(8)-11.37%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)180.11%
Min Revenue beat(2)180.11%
Max Revenue beat(2)180.11%
Revenue beat(4)4
Avg Revenue beat(4)6622.69%
Min Revenue beat(4)180.11%
Max Revenue beat(4)25950.4%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-65.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)99900%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 96.83 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.98 | ||
| P/tB | 5.98 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.14
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.04
BVpS0.57
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -117.04% | ||
| ROE | -176.38% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.92% | ||
| FCFM | N/A |
ROA(3y)-102.22%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 19.83% | ||
| Cap/Sales | 23.96% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.46 | ||
| Quick Ratio | 3.46 | ||
| Altman-Z | -3.73 |
F-Score3
WACC12.72%
ROIC/WACCN/A
Cap/Depr(3y)718.11%
Cap/Depr(5y)N/A
Cap/Sales(3y)3872.75%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.14%
EPS Next Y32.47%
EPS Next 2Y18.41%
EPS Next 3Y7.54%
EPS Next 5Y19.77%
Revenue 1Y (TTM)3100%
Revenue growth 3Y56.05%
Revenue growth 5YN/A
Sales Q2Q%0%
Revenue Next Year-6.67%
Revenue Next 2Y-5.13%
Revenue Next 3Y-3.45%
Revenue Next 5Y490.87%
EBIT growth 1Y0.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.34%
EBIT Next 3Y-21.4%
EBIT Next 5YN/A
FCF growth 1Y-135.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-139.27%
OCF growth 3YN/A
OCF growth 5YN/A
MIROMATRIX MEDICAL INC / MIRO Fundamental Analysis FAQ
What is the ChartMill fundamental rating of MIROMATRIX MEDICAL INC (MIRO) stock?
ChartMill assigns a fundamental rating of 3 / 10 to MIRO.
What is the valuation status of MIROMATRIX MEDICAL INC (MIRO) stock?
ChartMill assigns a valuation rating of 0 / 10 to MIROMATRIX MEDICAL INC (MIRO). This can be considered as Overvalued.
Can you provide the profitability details for MIROMATRIX MEDICAL INC?
MIROMATRIX MEDICAL INC (MIRO) has a profitability rating of 0 / 10.
Can you provide the expected EPS growth for MIRO stock?
The Earnings per Share (EPS) of MIROMATRIX MEDICAL INC (MIRO) is expected to grow by 32.47% in the next year.